With our in-house technology platform, scientific expertise in the inner ear, and network of experts, Sensorion can continually develop and optimize its pipeline and market expertise. Consequently, we are poised to expand our pipeline and facilitate other pharmaceutical collaborations.

We select and develop drug candidates from a pool of compounds in late pre-clinical and clinical stage development obtained from partnerships, collaborations and publically available drug libraries.

Sensorion has two therapeutic solutions being evaluated in clinical trials:
SENS-111 and SENS-401

20190603 pipeline

 

Latest news

  • 12 Jun 2019

    Sensorion announces a €20m convertible bond issue subscribed by two renowned investors Invus and Sofinnova Partners. Read

  • 03 Jun 2019

    Sensorion Announces Poster Presentation at the “Société Internationale d’Otoneurologie” Symposium. Read

Patient center

Corporate presentation